FK-506 - AN IMMUNOSUPPRESSANT FOR THE 1990S

A M MACLEOD, A W THOMSON

Research output: Contribution to journalLiterature review

49 Citations (Scopus)

Abstract

The novel macrolide immunosuppressant FK 506 is a powerful and selective anti-T-cell agent which has a similar mode of action to that of cyclosporin. Clinical studies of FK 506 in liver allograft recipients indicate a lower risk/benefit ratio than with cyclosporin, and wider evaluation of FK 506 in transplant recipients is now under way in multicentre, prospective, controlled trials in both Europe and North America.

Original languageEnglish
Pages (from-to)25-27
Number of pages3
JournalThe Lancet
Volume337
Issue number8732
Publication statusPublished - 5 Jan 1991

Keywords

  • PEPTIDYL-PROLYL ISOMERASE
  • RECEIVING FK-506
  • DRUG FK-506
  • FK506
  • TRANSPLANTATION
  • RATS
  • CYCLOSPORINE
  • COMBINATION
  • ACTIVATION
  • INHIBITION

Cite this

MACLEOD, A. M., & THOMSON, A. W. (1991). FK-506 - AN IMMUNOSUPPRESSANT FOR THE 1990S. The Lancet, 337(8732), 25-27.

FK-506 - AN IMMUNOSUPPRESSANT FOR THE 1990S. / MACLEOD, A M ; THOMSON, A W .

In: The Lancet, Vol. 337, No. 8732, 05.01.1991, p. 25-27.

Research output: Contribution to journalLiterature review

MACLEOD, AM & THOMSON, AW 1991, 'FK-506 - AN IMMUNOSUPPRESSANT FOR THE 1990S', The Lancet, vol. 337, no. 8732, pp. 25-27.
MACLEOD AM, THOMSON AW. FK-506 - AN IMMUNOSUPPRESSANT FOR THE 1990S. The Lancet. 1991 Jan 5;337(8732):25-27.
MACLEOD, A M ; THOMSON, A W . / FK-506 - AN IMMUNOSUPPRESSANT FOR THE 1990S. In: The Lancet. 1991 ; Vol. 337, No. 8732. pp. 25-27.
@article{3e9e35d57bb146e980c66acebe497b55,
title = "FK-506 - AN IMMUNOSUPPRESSANT FOR THE 1990S",
abstract = "The novel macrolide immunosuppressant FK 506 is a powerful and selective anti-T-cell agent which has a similar mode of action to that of cyclosporin. Clinical studies of FK 506 in liver allograft recipients indicate a lower risk/benefit ratio than with cyclosporin, and wider evaluation of FK 506 in transplant recipients is now under way in multicentre, prospective, controlled trials in both Europe and North America.",
keywords = "PEPTIDYL-PROLYL ISOMERASE, RECEIVING FK-506, DRUG FK-506, FK506, TRANSPLANTATION, RATS, CYCLOSPORINE, COMBINATION, ACTIVATION, INHIBITION",
author = "MACLEOD, {A M} and THOMSON, {A W}",
year = "1991",
month = "1",
day = "5",
language = "English",
volume = "337",
pages = "25--27",
journal = "The Lancet",
issn = "0140-6736",
publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",
number = "8732",

}

TY - JOUR

T1 - FK-506 - AN IMMUNOSUPPRESSANT FOR THE 1990S

AU - MACLEOD, A M

AU - THOMSON, A W

PY - 1991/1/5

Y1 - 1991/1/5

N2 - The novel macrolide immunosuppressant FK 506 is a powerful and selective anti-T-cell agent which has a similar mode of action to that of cyclosporin. Clinical studies of FK 506 in liver allograft recipients indicate a lower risk/benefit ratio than with cyclosporin, and wider evaluation of FK 506 in transplant recipients is now under way in multicentre, prospective, controlled trials in both Europe and North America.

AB - The novel macrolide immunosuppressant FK 506 is a powerful and selective anti-T-cell agent which has a similar mode of action to that of cyclosporin. Clinical studies of FK 506 in liver allograft recipients indicate a lower risk/benefit ratio than with cyclosporin, and wider evaluation of FK 506 in transplant recipients is now under way in multicentre, prospective, controlled trials in both Europe and North America.

KW - PEPTIDYL-PROLYL ISOMERASE

KW - RECEIVING FK-506

KW - DRUG FK-506

KW - FK506

KW - TRANSPLANTATION

KW - RATS

KW - CYCLOSPORINE

KW - COMBINATION

KW - ACTIVATION

KW - INHIBITION

M3 - Literature review

VL - 337

SP - 25

EP - 27

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8732

ER -